Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Cellectricon Launches Grant to Fund Electroporation-based Research

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
New Cellaxess® Project Grant supports advanced research projects.

As a provider of advanced cell-based screening technologies and services, Cellectricon is inviting researchers to apply for the recently launched Cellaxess Project Grant. The Grant is open to any scientist or research group wanting to capitalize on the advanced electromanipulation capabilities of the Cellaxess® platform for the cellular delivery of non-genetic material, particularly small molecules and peptides. Winners will be selected from two categories, basic and applied cell-based research, and will receive the Cellaxess ACE platform, along with all consumables and reagents, for a fully supported project. Interested groups should submit a research proposal by Wednesday 31st July, explaining how they intend to use the Cellaxess technology in their research project, using the application form available on Cellectricon’s website.

The Cellaxess electroporation system, which can be used for the in-situ transfection of any adherent cell-type, ensures minimal cell processing for perfectly retained cell function and morphology. As such, the platform is ideal for the delivery of non-genetic material, including antibodies, peptides and other small molecules, to challenging cells such as primary and IPS-derived neuronal cell types. Cellectricon welcomes proposals that exploit these unique capabilities of the Cellaxess system and, via the Cellaxess Project Grant, is keen to support and develop the proprietary work of research groups worldwide. Helping to expand the scope of such research, the Grant provides a unique opportunity for scientists to access cutting-edge technologies and gain first-hand advice from Cellectricon’s expert team.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellectricon, Censo Biotechnologies Collaborate
Collaboration aims to offer high-quality human iPSC-based discovery services for CNS and pain research.
Friday, September 09, 2016
Cellectricon, Neurexpert Announce Collaboration
Cellectricon and Neurexpert will co-promote their combined CNS drug discovery expertise, with a particular focus on synaptic function assays, for research into treatments of central nervous system disorders in the fields of psychiatry, neurology, pain and neurodegeneration.
Wednesday, June 08, 2016
Cellectricon and Neurexpert Collaborate To Offer Enhanced offering In CNS Drug Discovery
Company has announced its collaboration with Neurexpert Ltd to provide of advanced cell-based discovery services.
Wednesday, June 08, 2016
Cellectricon Establishes Scientific Advisory Board to Enhance Its Pain and CNS Discovery Services
The company, a leading provider of advanced cell-based discovery services, has appointed Dr Edwin Johnson, Director of The Stockholm Brain Institute, as the first member of its new Scientific Advisory Board.
Thursday, July 09, 2015
UCL’s Novel Approach to Research in Biologically-Relevant Models
Cellectricon and UCL unite to present a webinar, March 27, 11am-12pm EDT.
Wednesday, March 19, 2014
Cellectricon Announces Project Grant Winners
The grant was awarded for project proposals utilizing Cellectricon’s Cellaxess ACE technology for the delivery of non-genetic material to adherent cells and cultures.
Thursday, September 19, 2013
Presenting Phenotypic Screening Strategies for Chronic Pain Research
Cellectricon explores novel phenotypic assay designs in a webinar, 5 September, 11am-12pm (EDT).
Wednesday, August 21, 2013
Identifying Unknown Modulators of Pain with New Phenotypic Assays
Cellectricon presentation: SMi Pain Therapeutics conference, 20 May, 11am.
Tuesday, May 14, 2013
Dr. Paul Karila appointed Head of Discovery Services at Cellectricon AB
Discovery services will be based on automated cellular electric field manipulation for novel screening applications.
Wednesday, June 13, 2012
Cellectricon Receives Milestone Order for Cellaxess®HT High Throughput RNAi Screening System
Cellectricon receives the largest single order to deliver three Cellaxess®HT systems to a leading US biotech firm.
Friday, November 14, 2008
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Structure of Primary Cannabinoid Receptor is Revealed
The findings provide key insights into how natural and synthetic cannabinoids including tetrahydrocannabinol —a primary chemical in marijuana—bind at the CB1 receptor to produce their effects.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Agilent Presents Early Career Professor Award to Dr. Roeland Verhaak
JAX professor recognized for the development and implementation of workflows for the analysis of big-data from transcriptomics to next generation sequencing approaches.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos